Home Technology Computer Vision NEC and Biomy Partner in the Development and Expansion of AI-Based Analytical...

NEC and Biomy Partner in the Development and Expansion of AI-Based Analytical platforms in the Digital Pathology Field.

0
NEC and Biomy Partner in the Development and Expansion of AI-Based Analytical platforms in the Digital Pathology Field.

NEC and Biomy Partner in the Development and Expansion of AI-Based Analytical platforms in the Digital Pathology Field.

(JCN Newswire), TOKYO, January 10, 2025. NEC Corporation, (NEC, TSE: 6701), and Biomy, Inc., (Biomy), have signed a Memorandum of Understanding for a joint Marketing Partnership to develop and expand analytical platforms based on artificial intelligence/deep-learning (AI The two companies hope to advance the healthcare industry through this partnership and promote precision medicine. Background

Precision Medicine, which selects more effective treatments that have fewer side effects based on the unique characteristics of each patient and their disease profile, has become increasingly popular. In pathology diagnosis(2), AI/DL algorithms are being used to analyze digital images to identify pathological markers(3) that can stratify and facilitate the selection and use of the most promising and patient-tailored treatments and drugs.

The Partnership’s Objectives

NEC, as a company that creates social value by solving societal problems through advanced technology, has made healthcare and life sciences a key pillar in its growth strategy. NEC, with its strong foundation in AI technologies and image analysis, has a long-standing history of providing medical information to healthcare institutions. This includes electronic medical records. NEC also has a license to manufacture and market Class I medical products in Japan. This shows that NEC is well-versed in the regulatory approval process for medical devices. This includes AI/DL based digital pathology systems.

Biomy, which aims to realize personalized medicine through pathological AI technology, has developed DeepPathFinder(tm),(4), a proprietary, cloud-based, AI/DL automated digital pathology analytical platform. This platform analyzes digital images to classify tissue and cell types in specific areas. It also offers the unique capability to detect immune cells, such as lymphocytes or plasma cells(5), from hematoxylin-eosin stained images6 along with spatial features. It also quantifies characteristics relating to drug efficacy, prognosis and other factors. DeepPathFinder ™ can improve the accuracy and efficiency of digital pathology analyses. This partnership integrates cutting-edge AI technology developed by NEC with Biomy to enhance the DeepPathFinder ™ platform. The primary objectives are to enhance the DeepPathFinder ™ platform in order for it discover new pathological biomarkers using AI/DL-based digital image analysis. It also aims at leveraging data derived from the pathological images and supporting precision medicine and treatment plans, especially in the area of cancer care. The resulting AI/DL-driven pathological biomarker discovery tool will then be offered to pharmaceutical/biotech companies and academia through the provision of the following:

  1. An automated digital pathology platform for independently exploring pathological biomarkers from pathology images.
  2. Full digital pathological biomarker services provided through partnerships with NEC, Biomy and Biomy.
  3. Guidance, support and assistance in obtaining regulatory approvals for medical devices that use the newly discovered pathological markers.

Future developments

NEC and Biomy hope to make a significant contribution to the future of medicine and deliver precision medicine to cancer sufferers by advancing next-generation AI/DL based pathology analysis platforms. (1) Digital pathology is a field that involves the digitization of pathology slides and their computational analysis.
2) Pathology diagnostics – The study and diagnosis disease by examining organs, tissues and cells.
3) Pathological biomarkers : Biological markers that can be identified through pathology and used to stratify patients or predict treatment responses. In this press release biomarkers identified by morphological features in pathological images are called “pathological biomarkers.”
; (4) DeepPathFinder ™: The platform is only for research purposes, not for clinical applications.
Lymphocytes and Plasma Cells: Lymphocytes, a type white blood cell, are immune-related cells that can be classified into T cells (white blood cells), B cells (white blood cells), and NK cells. Plasma cells are mature B cells that produce anti-bodies and play a critical role in attacking cancerous cells. They provide insights into individual immune response and tumor characteristics. This evaluation can help determine the effectiveness or specific treatments, and also contribute to the selection of patients who are most suitable for clinical trials. It can also be used to develop treatment strategies and personalize medicine. (6) Hematoxylin-eosin staining (H&E). This is the most common staining method used in pathological histological diagnoses, and it is always done in conjunction with a light microscopy.

NEC Corporation

NEC Corporation is a leader in integrating IT and network technology while promoting its brand statement “Orchestrating a brighter World.” NEC Corporation enables businesses and community to adapt to rapid change taking place in society and market, as it provides social values such as safety, security and fairness to promote a sustainable world where everyone can reach their full potential. Visit NEC at https://www.nec.com for more information.

Copyright (c)2025 JCN Newswire. All rights reserved. All rights reserved.

Read More

NO COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Exit mobile version

Notice: ob_end_flush(): Failed to send buffer of zlib output compression (0) in /home2/mflzrxmy/public_html/website_18d00083/wp-includes/functions.php on line 5464